AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 18357902 — intervention group
Group type: EXPERIMENTAL
Intervention: Hip abductors
Number of subjects: 40
Study 18357902 — intervention group
Group type: EXPERIMENTAL
Intervention: Hip adductors
Number of subjects: 40
Study 15680926 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-delivered behavioral regimen (progressive relaxation, limited biofeedback with autogenic training, and stress management)
Number of subjects: 0
Study 15680926 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-delivered behavioral regimen
Number of subjects: 0
Study 15680926 — intervention group
Group type: COMPARATOR
Intervention: Symptom monitoring waitlist control
Number of subjects: 0
Study 12042231 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief cognitive-behavioural therapy (CBT), n=257
Number of subjects: 422
Study 12042231 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (control group), n=165
Number of subjects: 422
Study 10192710 — intervention group
Group type: EXPERIMENTAL
Intervention: BCG vaccine given simultaneously with DTaP vaccine
Number of subjects: 390
Study 10192710 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-4-6-month spaced schedule
Number of subjects: 390
Study 10192710 — intervention group
Group type: COMPARATOR
Intervention: 2-3-4-month accelerated schedule
Number of subjects: 390
Study 7762855 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1 mg/kg diltiazem
Number of subjects: 80
Study 7762855 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2 mg/kg diltiazem
Number of subjects: 80
Study 7762855 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg/kg lidocaine
Number of subjects: 80
Study 7762855 — intervention group
Group type: COMPARATOR
Intervention: saline
Number of subjects: 80
Study 1702899 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoprinosine 3 g/day for 28 days
Number of subjects: 8
Study 1702899 — intervention group
Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 8
Study 1702899 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoprinosine
Number of subjects: 8
Study 6775742 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous intravenous infusion of papaveretum (1 mg/min loading dose, followed by 8 times the loading dose over 48 hours)
Number of subjects: 0
Study 6775742 — intervention group
Group type: COMPARATOR
Intervention: Intermittent intramuscular dose of papaveretum (0.25 mg/kg at four hourly intervals as necessary)
Number of subjects: 0
Study 31886526 — intervention group
Group type: EXPERIMENTAL
Intervention: Multicomponent programs incorporating exercise and nutrition-based strategies
Number of subjects: 0
Study 31886526 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmaceutical and other innovative therapeutic strategies
Number of subjects: 0
Study 31886526 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study 31020742 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored education (six 45-60 min individual education and follow-up telephone counselling sessions)
Number of subjects: 69
Study 31020742 — intervention group
Group type: COMPARATOR
Intervention: Standard of care only
Number of subjects: 69
Study 28211797 — intervention group
Group type: EXPERIMENTAL
Intervention: TTM intervention
Number of subjects: 126
Study 25596266 — intervention group
Group type: EXPERIMENTAL
Intervention: rituximab-cyclophosphamide-doxorubicin-vincristine-prednisone
Number of subjects: 428
Study 25596266 — intervention group
Group type: COMPARATOR
Intervention: rituximab-cyclophosphamide-vincristine-prednisone
Number of subjects: 428
Study 25596266 — intervention group
Group type: COMPARATOR
Intervention: rituximab-fludarabine-mitoxantrone
Number of subjects: 428
Study 24135720 — intervention group
Group type: EXPERIMENTAL
Intervention: 16 weeks of continuously supervised moderate-to-high intensity aerobic exercise
Number of subjects: 192
Study 24135720 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 192
Study 21666937 — intervention group
Group type: EXPERIMENTAL
Intervention: Stepwise stent deployment (SSD)
Number of subjects: 403
Study 21666937 — intervention group
Group type: COMPARATOR
Intervention: Conventional stent deployment (CSD)
Number of subjects: 403
Study 19425875 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous glucose monitoring with real-time access (RTA)
Number of subjects: 50
Study 19425875 — intervention group
Group type: COMPARATOR
Intervention: Continuous glucose monitoring with retrospective analysis (RA)
Number of subjects: 50
Study 19425875 — intervention group
Group type: COMPARATOR
Intervention: Baseline satisfaction with CGM
Number of subjects: 50
Study 19425875 — intervention group
Group type: EXPERIMENTAL
Intervention: Depression scores
Number of subjects: 50
Study 19425875 — intervention group
Group type: COMPARATOR
Intervention: Diabetes-related distress
Number of subjects: 50
Study 19425875 — intervention group
Group type: COMPARATOR
Intervention: State anxiety
Number of subjects: 50
Study 16961448 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-S therapy (8 weeks)
Number of subjects: 72
Study 16961448 — intervention group
Group type: COMPARATOR
Intervention: Standard care alone
Number of subjects: 72
Study 15580055 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel
Number of subjects: 0
Study 15580055 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 10697060 — intervention group
Group type: EXPERIMENTAL
Intervention: Estrogen 0.625 mg/d
Number of subjects: 120
Study 10697060 — intervention group
Group type: EXPERIMENTAL
Intervention: Estrogen 1.25 mg/d
Number of subjects: 120
Study 10697060 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 10697060 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined estrogen groups
Number of subjects: 120
Study 9328698 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary angioplasty
Number of subjects: 37598
Study 9328698 — intervention group
Group type: COMPARATOR
Intervention: Thrombolytic therapy
Number of subjects: 37598
Study 8223057 — intervention group
Group type: EXPERIMENTAL
Intervention: Nd:YAG laser
Number of subjects: 86
Study 8223057 — intervention group
Group type: COMPARATOR
Intervention: Scalpel excision
Number of subjects: 86
Study 3544189 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine (400 mg at night)
Number of subjects: 75
Study 3544189 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose antacid (400 mg of aluminum hydroxide plus 400 mg of magnesium hydroxide four times a day)
Number of subjects: 75
Study 3544189 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (cimetidine and low-dose antacid)
Number of subjects: 75
Study 30388194 — intervention group
Group type: EXPERIMENTAL
Intervention: Tafenoquine (n = 12), single 200-mg dose on days 1, 2, 3, and 10
Number of subjects: 16
Study 30388194 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 4)
Number of subjects: 16
Study 29565608 — intervention group
Group type: EXPERIMENTAL
Intervention: Listening Passage Preview (LPP) + Repeated Readings (RR)
Number of subjects: 57
Study 29565608 — intervention group
Group type: COMPARATOR
Intervention: Repeated Readings (RR)
Number of subjects: 57
Study 26741823 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fiber white rice (HFWR)
Number of subjects: 30
Study 26741823 — intervention group
Group type: COMPARATOR
Intervention: Commercial white rice (WR)
Number of subjects: 30
Study 25066555 — intervention group
Group type: EXPERIMENTAL
Intervention: Implantable monitoring device (IMD) with alerting feature turned on
Number of subjects: 0
Study 25066555 — intervention group
Group type: COMPARATOR
Intervention: Implantable monitoring device (IMD) with alerting feature turned off
Number of subjects: 0
Study 22914392 — intervention group
Group type: EXPERIMENTAL
Intervention: Progesterone treatment (n=258)
Number of subjects: 523
Study 22914392 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment (n=265)
Number of subjects: 523
Study 22914392 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-8 levels at 18-24 weeks of gestation
Number of subjects: 523
Study 19892086 — intervention group
Group type: EXPERIMENTAL
Intervention: Manualized and workbook-driven individual cognitive-behavioral treatment for social anxiety disorder
Number of subjects: 38
Study 19892086 — intervention group
Group type: COMPARATOR
Intervention: Delayed treatment for 20 weeks
Number of subjects: 38
Study 17684877 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg hyperbaric bupivacaine 0.5% + 25 microg fentanyl
Number of subjects: 60
Study 17684877 — intervention group
Group type: EXPERIMENTAL
Intervention: 7.5 mg hyperbaric bupivacaine 0.5% + 25 microg fentanyl
Number of subjects: 60
Study 17684877 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg hyperbaric bupivacaine 0.5% + 25 microg fentanyl
Number of subjects: 60
Study 15862475 — intervention group
Group type: EXPERIMENTAL
Intervention: Induced catastrophizing about pain
Number of subjects: 0
Study 15862475 — intervention group
Group type: COMPARATOR
Intervention: Control (no induced catastrophizing)
Number of subjects: 0
Study 12532901 — intervention group
Group type: EXPERIMENTAL
Intervention: Glutamine
Number of subjects: 36
Study 12532901 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 9650877 — intervention group
Group type: EXPERIMENTAL
Intervention: Herbal extract mouthwash (6.3 mg/ml)
Number of subjects: 45
Study 9650877 — intervention group
Group type: COMPARATOR
Intervention: Minus active control mouthrinse
Number of subjects: 45
Study 8583518 — intervention group
Group type: EXPERIMENTAL
Intervention: Recovery Attitude and Treatment Evaluator (RAATE) completed by patients
Number of subjects: 0
Study 8583518 — intervention group
Group type: COMPARATOR
Intervention: Recovery Attitude and Treatment Evaluator (RAATE) completed by clinicians
Number of subjects: 0
Study 8583518 — intervention group
Group type: EXPERIMENTAL
Intervention: Less than 1 month of treatment
Number of subjects: 0
Study 2678688 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose interferon (100 x 10(6) IU)
Number of subjects: 19
Study 2678688 — intervention group
Group type: COMPARATOR
Intervention: Low-dose interferon (10 x 10(6) IU)
Number of subjects: 19
Study 2678688 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravesical interferon
Number of subjects: 19
Study 782141 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous aminophylline
Number of subjects: 79
Study 782141 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 79
Study 31162569 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based strength and balance retraining exercise program delivered by a physical therapist (n=173)
Number of subjects: 345
Study 31162569 — intervention group
Group type: COMPARATOR
Intervention: Usual care provided by a geriatrician (n=172)
Number of subjects: 345
Study 28349667 — intervention group
Group type: COMPARATOR
Intervention: High-glycemic-index diet (HiGIX; 80 +/- 0.6 units) combined with supervised exercise (1 h/d, 5 d/wk at 85% HRmax) for 12 weeks
Number of subjects: 19
Study 28349667 — intervention group
Group type: COMPARATOR
Intervention: Low-glycemic-index diet (LoGIX; 40 +/- 0.3 units) combined with supervised exercise (1 h/d, 5 d/wk at 85% HRmax) for 12 weeks
Number of subjects: 19
Study 24451365 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced balance and postural control exercises (EB)
Number of subjects: 23
Study 24451365 — intervention group
Group type: COMPARATOR
Intervention: Standard balance exercises (SB)
Number of subjects: 23
Study 24050377 — intervention group
Group type: EXPERIMENTAL
Intervention: BP card with added semi-structured nurse counseling
Number of subjects: 0
Study 24050377 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study 24050377 — intervention group
Group type: COMPARATOR
Intervention: BP card only (not explicitly mentioned but implied as part of usual care)
Number of subjects: 0
Study 21975132 — intervention group
Group type: EXPERIMENTAL
Intervention: REFLEX intervention (12 sessions group training)
Number of subjects: 0
Study 21975132 — intervention group
Group type: COMPARATOR
Intervention: Active control condition (cognitive remediation exercises in a group)
Number of subjects: 0
Study 17910386 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 h/night sleep
Number of subjects: 18
Study 17910386 — intervention group
Group type: COMPARATOR
Intervention: 8 h/night sleep
Number of subjects: 18
Study 16254264 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium-citrate plasma
Number of subjects: 80
Study 16254264 — intervention group
Group type: COMPARATOR
Intervention: Serum
Number of subjects: 80
Study 12440605 — intervention group
Group type: EXPERIMENTAL
Intervention: Port access CABG (group B)
Number of subjects: 40
Study 12440605 — intervention group
Group type: COMPARATOR
Intervention: Conventional CABG (group A)
Number of subjects: 40
Study 12440605 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 40
Study 10208143 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxandrolone, 20 mg/d
Number of subjects: 24
Study 10208143 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 7885427 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal nicotine patches (15 mg for 16 hours daily)
Number of subjects: 80
Study 7885427 — intervention group
Group type: COMPARATOR
Intervention: Placebo patches
Number of subjects: 80
Study 7885427 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal nicotine patches
Number of subjects: 80
Study 2515940 — intervention group
Group type: EXPERIMENTAL
Intervention: Levonorgestrel (LNG)
Number of subjects: 33
Study 2515940 — intervention group
Group type: EXPERIMENTAL
Intervention: Gestodene (GES)
Number of subjects: 33
Study 356980 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent bolus DTIC and actinomycin D (starting at 650 mg/m2 and 1 mg/m2 respectively, courses repeated at 3-4 week intervals)
Number of subjects: 26
Study 356980 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent bolus DTIC and actinomycin D
Number of subjects: 26
Study 30538068 — intervention group
Group type: COMPARATOR
Intervention: Systemic therapy-naive patients with BM
Number of subjects: 268
Study 30538068 — intervention group
Group type: EXPERIMENTAL
Intervention: Matched patients without BM
Number of subjects: 268
Study 30538068 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with BM in favorable-risk group
Number of subjects: 268
Study 30538068 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with BM in intermediate-risk group
Number of subjects: 268
Study 30538068 — intervention group
Group type: COMPARATOR
Intervention: Patients without BM in intermediate-risk group
Number of subjects: 268
Study 30538068 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with BM in poor-risk group
Number of subjects: 268
Study 30538068 — intervention group
Group type: COMPARATOR
Intervention: Patients without BM in poor-risk group
Number of subjects: 268
Study 30538068 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients developing BM while on first-line systemic therapy
Number of subjects: 268
Study 30538068 — intervention group
Group type: COMPARATOR
Intervention: Patients without BM while on first-line systemic therapy
Number of subjects: 268
Study 27756786 — intervention group
Group type: EXPERIMENTAL
Intervention: Degarelix only
Number of subjects: 39
Study 27756786 — intervention group
Group type: EXPERIMENTAL
Intervention: Degarelix/bicalutamide
Number of subjects: 39
Study 27756786 — intervention group
Group type: COMPARATOR
Intervention: LHRH agonist/bicalutamide
Number of subjects: 39
Study 29392002 — intervention group
Group type: EXPERIMENTAL
Intervention: Adenoid vegetation with Dermatophagoides Pteronyssinus and/or D. farinae allergy (Group II)
Number of subjects: 84
Study 29392002 — intervention group
Group type: COMPARATOR
Intervention: Adenoid vegetation only (Group I)
Number of subjects: 84
Study 24119182 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol 12.5/25 mg daily
Number of subjects: 75
Study 24119182 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol 50/100 mg daily
Number of subjects: 75
Study 24119182 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebivolol 2.5/5 mg daily
Number of subjects: 75
Study 21428248 — intervention group
Group type: EXPERIMENTAL
Intervention: Thymol + eugenol vaginal douche (SD) 1 douche/day for 1 week
Number of subjects: 459
Study 21428248 — intervention group
Group type: COMPARATOR
Intervention: Metronidazole vaginal suppository 1/night for 1 week
Number of subjects: 459
Study 21428248 — intervention group
Group type: COMPARATOR
Intervention: Econazole vaginal suppository 1/night for 3 days
Number of subjects: 459
Study 19427775 — intervention group
Group type: EXPERIMENTAL
Intervention: Crocus sativus (saffron) 200mg tablet taken daily for ten days
Number of subjects: 20
Study 16997936 — intervention group
Group type: EXPERIMENTAL
Intervention: DHEA treatment (75 mg daily for an average of 17.6 weeks)
Number of subjects: 25
Study 14691415 — intervention group
Group type: EXPERIMENTAL
Intervention: Vascular closure devices (CDs)
Number of subjects: 4736
Study 14691415 — intervention group
Group type: COMPARATOR
Intervention: Manual compression (MC)
Number of subjects: 4736
Study 12003058 — intervention group
Group type: EXPERIMENTAL
Intervention: Venlafaxine
Number of subjects: 459
Study 12003058 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 459
Study 12003058 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipramine
Number of subjects: 459
Study 9785763 — intervention group
Group type: EXPERIMENTAL
Intervention: IMZ SPECT with 123I‐IMZ (167 or 222 MBq)
Number of subjects: 17
Study 9785763 — intervention group
Group type: EXPERIMENTAL
Intervention: IMZ SPECT
Number of subjects: 17
Study 7697142 — intervention group
Group type: EXPERIMENTAL
Intervention: Red cedar dust delivered through a rotahaler
Number of subjects: 9
Study 7697142 — intervention group
Group type: COMPARATOR
Intervention: Spruce dust (control)
Number of subjects: 9
Study 2487936 — intervention group
Group type: EXPERIMENTAL
Intervention: Warmed 0.5% bupivacaine at 37 degrees C
Number of subjects: 40
Study 2487936 — intervention group
Group type: COMPARATOR
Intervention: Glucose-free 0.5% bupivacaine at room temperature (approximately 20 degrees C)
Number of subjects: 40
Study 363252 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate alone
Number of subjects: 282
Study 363252 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate plus mercaptopurine
Number of subjects: 282
Study 363252 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate plus mercaptopurine plus cyclophosphamide
Number of subjects: 282
Study 363252 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate plus mercaptopurine plus cyclophosphamide plus arabinosyl cytosine
Number of subjects: 282
Study 363252 — intervention group
Group type: EXPERIMENTAL
Intervention: Additional early therapy
Number of subjects: 282
Study 30861594 — intervention group
Group type: EXPERIMENTAL
Intervention: Provision of free diabetes supplies
Number of subjects: 85
Study 30861594 — intervention group
Group type: EXPERIMENTAL
Intervention: Proactive telephonic advice by a diabetes educator
Number of subjects: 85
Study 30861594 — intervention group
Group type: COMPARATOR
Intervention: Usual care (non-telephone group)
Number of subjects: 85
Study 28324754 — intervention group
Group type: EXPERIMENTAL
Intervention: TENS group (n=20)
Number of subjects: 40
Study 28324754 — intervention group
Group type: COMPARATOR
Intervention: Sham group (n=20)
Number of subjects: 40
Study 25472980 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug-coated balloon (DCB)
Number of subjects: 331
Study 25472980 — intervention group
Group type: COMPARATOR
Intervention: Percutaneous transluminal angioplasty (PTA)
Number of subjects: 331
Study 22841131 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 29
Study 22841131 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-Behavioral Therapy (CBT)
Number of subjects: 29
Study 21860053 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 198
Study 21860053 — intervention group
Group type: COMPARATOR
Intervention: Cognitive Remediation (CR)
Number of subjects: 198
Study 19420003 — intervention group
Group type: EXPERIMENTAL
Intervention: Single intracoronary infusion of bone marrow mononuclear cells (BMC) (1.9 +/- 1.2 x 10^8) at 3-7 days after AMI
Number of subjects: 39
Study 19420003 — intervention group
Group type: EXPERIMENTAL
Intervention: BMC administration both at 3-7 days (2.0 +/- 1.4 x 10^8) and at 3 months (2.1 +/- 1.7 x 10^8)
Number of subjects: 39
Study 19420003 — intervention group
Group type: COMPARATOR
Intervention: Placebo injection at 3-7 days
Number of subjects: 39
Study 17605559 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone-based individualized feedback
Number of subjects: 239
Study 17605559 — intervention group
Group type: EXPERIMENTAL
Intervention: Print-based individualized feedback
Number of subjects: 239
Study 17605559 — intervention group
Group type: COMPARATOR
Intervention: Contact control
Number of subjects: 239
Study 14736927 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin-based chemotherapy (at least 240 mg/m²); 932 patients assigned to chemotherapy
Number of subjects: 1867
Study 14736927 — intervention group
Group type: COMPARATOR
Intervention: Observation; 935 patients assigned to observation
Number of subjects: 1867
Study 11561496 — intervention group
Group type: EXPERIMENTAL
Intervention: Lateral position
Number of subjects: 74
Study 11561496 — intervention group
Group type: COMPARATOR
Intervention: Supine position
Number of subjects: 74
Study 9784911 — intervention group
Group type: EXPERIMENTAL
Intervention: Dipyridamole (300 mg/d) for 6 months
Number of subjects: 22
Study 9784911 — intervention group
Group type: EXPERIMENTAL
Intervention: Dilazep (300 mg/d) for 6 months
Number of subjects: 22
Study 7870560 — intervention group
Group type: EXPERIMENTAL
Intervention: Depressed mood group
Number of subjects: 40
Study 7870560 — intervention group
Group type: COMPARATOR
Intervention: Nondepressed group
Number of subjects: 40
Study 2832764 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination chemotherapy with thoracic irradiation (protocol 78 LUN 328)
Number of subjects: 660
Study 2832764 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination chemotherapy with simultaneous radiotherapy (protocol LUN 81343)
Number of subjects: 660
Study 2832764 — intervention group
Group type: COMPARATOR
Intervention: Combination chemotherapy alone (control group)
Number of subjects: 660
Study 2832764 — intervention group
Group type: EXPERIMENTAL
Intervention: Local control at 12 months (both protocols)
Number of subjects: 660
Study 30514660 — intervention group
Group type: EXPERIMENTAL
Intervention: CFS label
Number of subjects: 207